[ad_1]
In the past two years, few, if any, industries have been as impressive as the legal cannabis industry. With Canada becoming the first industrialized country in the world to hold the green flag for the adult pot, and more than 40 countries giving medical marijuana the go-ahead, Wall Street and investors are clearly waiting for big things in this industry.
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "How do we know this? Look no further than Marijuana stock valuation. Previously, long-term investments were considered early 2017, there are now 14 pot shares with a market capitalization of at least $ 1 billion (sorry, OrganiGram Holdings, you missed the cut of only $ 3 million), until April 25th. Let's take a look at the world's largest publicly traded marijuana stocks, as well as their respective market capitalizations. "data-reactid =" 12 "> Do not hesitate further than marihuana stock valuations, which were previously considered as long-term investments in early 2017. There are now 14" pot "stocks with market capitalization at least $ 1 billion OrganiGram Holdings, you missed the cut of only $ 3 million), until April 25th. Let's take a look at the world's largest pure-rated marijuana stocks and their respective market capitalization.
A handful of cannabis buds lie on top of a pile of bills in cash.
Source of the image: Getty Images.
<h2 class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "1. Cover Growth: $ 16.64 Billion "data-reactid =" 34 ">1. Cover Growth: $ 16.64 Billion
<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "With a few exceptions, Cover growth (NYSE: CGC) has been part of the world's largest pot stock for most of the past two years; and for a good reason. Canopy has more cash and cash equivalents (thanks to a huge $ 4 billion of equity investment of Constellation Brands) than any other growing pot, and is expected to be Canada's second largest annual producer, with more than 4.4 million square feet of its already authorized 5.6 million square feet of cultivation space. The department of branding and international expansion is not left out, with the most recognized brand in Canada (Tweed) and access to more than a dozen Overseas markets. "Data-reactid =" 35 "> With few exceptions, Cover growth (NYSE: CGC) has been part of the world's largest pot stock for most of the past two years; and for a good reason. Canopy has more cash and cash equivalents (thanks to a massive $ 4 billion equity investment from Constellation Brands) than any other growing pot, and is expected to be Canada's second largest annual producer, with more than 4.4 million square feet of its already authorized 5.6 million square feet of cultivation space. The department of branding and international expansion is not left out, with the most recognized brand in Canada (Tweed) and access to more than a dozen foreign markets.
<h2 class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "2. Aurora Cannabis: $ 9.22 billion "data-reactid =" 36 ">2. Aurora Cannabis: $ 9.22 billion
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Aurora Cannabis (NYSE: ACB) is probably the most popular pot stock among millennia. More importantly, he should also be the first Canadian producer. Although management projects are more like 500,000 kilograms of annual maximum pot production per year at full capacity, your forecast is very real. up to 780,000 pounds per year by 2022. Much of this output is the result of Aurora's aggressive acquisition strategy that has engulfed MedReleaf for $ 2 billion, CanniMed for $ 850 million and US laboratories ICC Labs for $ 200 million. Cherry on the cake, Aurora Cannabis is also present in more countries (24) than any other pot stock. "Data-reactid =" 37 ">Aurora Cannabis (NYSE: ACB) is probably the most popular pot stock among millennia. More importantly, he should also be the first Canadian producer. Although management projects more than 500,000 kilograms of annual maximum pot production per year at full capacity, yours is forecasting up to 780,000 kilograms per year by 2022. Much of this Production is the result of Aurora's aggressive acquisition strategy that has engulfed MedReleaf for $ 2 billion, CanniMed for $ 850 million and ICC Labs in South America for $ 200 million. . Cherry on the cake, Aurora Cannabis is also present in more countries (24) than any other pot stock.
<h2 class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "3. Cronos Group: $ 5.52 billion "data-reactid =" 38 ">3. Cronos Group: $ 5.52 billion
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Having recently joined the third rank, Cronos Group (NASDAQ: CRON) has benefited from $ 1.8 billion capital investment of the tobacco giant Altria, which closed in March. The investment has enabled Altria to acquire a non-diluted 45% stake in Cronos, but above all to provide Cronos with the working capital needed to increase its production capacity, diversify its product range, strengthen its brands and expand its business. to establish in foreign markets. With perhaps 120,000 kilos of peak annual output and a presence in only four overseas countries, Cronos definitely needed this money to carry out its long-term strategy. "Data-reactid =" 39 "> After recently being ranked third, Cronos Group (NASDAQ: CRON) benefited from a $ 1.8 billion investment by the giant tobacco Altria, which closed in March. The investment has enabled Altria to acquire a non-diluted 45% stake in Cronos, but above all to provide Cronos with the working capital needed to increase its production capacity, diversify its product range, strengthen its brands and expand its business. to establish in foreign markets. With perhaps 120,000 kilos of peak annual output and a presence in only four overseas countries, Cronos definitely needed this money to carry out its long-term strategy.
An Epidiolex vial next to its packaging and two droppers.
Source of image: GW Pharmaceuticals.
<h2 class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "4. GW Pharmaceuticals: $ 4.99 billion "data-reactid =" 65 ">4. GW Pharmaceuticals: $ 4.99 billion
<p class = "canvas-atom web-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The only developer of cannabinoid drugs to play pure of the group is GW Pharmaceuticals (NASDAQ: GWPH). In June 2018, GW Pharmaceuticals' flagship drug, the oral cannabidiol (CBD) treatment, Epidiolex, was approved by the US Food and Drug Administration (FDA). This follows a unanimous recommendation by the FDA for approval a week earlier. Epidiolex has finally reduced the frequency of onset seizures by 30% to 40% in multiple late-stage trials in patients with Dravet syndrome or Lennox-Gastaut syndrome and is now the only approved treatment for Dravet syndrome. "Data-reactid =" 66 "> The only developer of cannabinoid-based drugs in the game is GW Pharmaceuticals (NASDAQ: GWPH). In June 2018, GW Pharmaceuticals' flagship drug, oral cannabidiol (CBD) treatment, Epidiolex, was approved by the Food and Drug Administration (FDA). This follows a unanimous recommendation by the FDA for approval a week earlier. Epidiolex ultimately reduced the frequency of onset seizures from 30% to 40% in multiple end-stage trials in patients with Dravet syndrome or Lennox-Gastaut syndrome. It is now one of the only approved treatments for Dravet syndrome.
<h2 class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "5. Tilray: $ 4.96 billion "data-reactid =" 67 ">5. Tilray: $ 4.96 billion
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "How powerful have fallen." After briefly dethroning Growth of the canopy for the first place, Tilray (NASDAQ: TLRY) has seen its market capitalization return to less than $ 5 billion. Although Tilray has done impressive work in strengthening its medical cannabis brands in Canada, it has also expanded into new markets, recently announced strategy change for Tilray to focus on the European Union and the United States, while minimizing Canada's attention, left investors scratching their heads. In addition, with only about 100,000 kilos at the moment, investors are clearly wondering when Tilray will increase its production capacity. "Data-reactid =" 68 "> The fall of the powerful has already dethroned briefly Growth of the canopy for the summit place, Tilray (NASDAQ: TLRY) has seen its market capitalization return to less than $ 5 billion. Although Tilray has done impressive work in strengthening its medical cannabis brands in Canada and expanding into new markets, a recently announced strategy shift allows it to focus on the European Union and the United States. left investors scratching their heads. In addition, with a peak production of around 100,000 kilos at the moment, investors are clearly wondering when Tilray will increase its production capacity.
<h2 class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "6. Curaleaf Holdings: $ 4.82 billion "data-reactid =" 69 ">6. Curaleaf Holdings: $ 4.82 billion
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "At the sixth point, but at a typing distance of one of the first three places is Curaleaf Holdings (NASDAQOTH: CURLF), the largest vertically integrated dispensary operator in the United States, at least by market capitalization. Vertically integrated retailers such as Curaleaf control their entire supply chain, which is necessary to reduce costs, ensure quality control and stay in compliance with US and federal cannabis laws. Currently, Curaleaf has 43 open stores, 12 culture farms and 11 processing sites, but plans to create nearly 70 clinics open by the end of the year. It has also recently concluded an agreement to sell some of its CBD-rich hemp products to the UK. CVS Health"data-reactid =" 70 "> In sixth place, but at a striking distance of the first three places, Curaleaf Holdings (NASDAQOTH: CURLF), the largest vertically integrated dispensary operator in the United States, at least by market capitalization. Vertically integrated retailers such as Curaleaf control their entire supply chain, which is necessary to reduce costs, ensure quality control and stay in compliance with US and federal cannabis laws. At present, Curaleaf has 43 open retail stores, 12 growing operations and 11 processing sites, but expects to create nearly 70 open clinics by the end of the year. It has also recently concluded an agreement to sell some of its CBD-rich hemp products to the UK. CVS Health.
A large pharmacy sign, with a cannabis leaf and the word "dispensary" written below.
Source of the image: Getty Images.
<h2 class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "7. Harvest health & amp; Recreation: $ 2.67 billion "data-reactid =" 92 ">7. Harvest Health & Recreation: $ 2.67 billion
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Even if there is a significant drop in market capitalization between Curaleaf at No. 6 and Harvest health & amp; Recreation (NASDAQOTH: HRVSF) at No. 7, it does not make less impressive what Harvest Health has done. Harvest Health currently has only 10 open outlets in four states, but a number of major acquisitions, including the $ 850 million stock agreement to purchase Verano Holdings, a private company. will catapult its number of retail, culture and processing licenses. . If all outstanding transactions are concluded, Harvest Health will have 213 licenses in total, including the right to open 130 retail outlets, which is high among publicly traded dispensary operators. "data-reactid =" 93 "> Even if there is a significant drop in the market capitalization between Curaleaf at n ° 6 and Harvest Health & Recreation (NASDAQOTH: HRVSF) at No. 7, it does not make less impressive what Harvest Health has done. Harvest Health currently has only 10 open outlets in four states, but a number of major acquisitions, including the $ 850 million stock agreement to purchase Verano Holdings, a private company. will catapult its number of retail, culture and processing licenses. . If all outstanding transactions are concluded, Harvest Health will have 213 licenses in total, including the right to open 130 retail outlets, which is one of the best among listed dispensary operators. in stock exchange.
<h2 class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "8. Holdings: $ 2.54 billion "data-reactid =" 94 ">8. Holdings: $ 2.54 billion
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "It is perhaps not surprising that the eighth biggest stock pot is Surface Fund (NASDAQOTH: ACRGF), a vertically integrated dispensary operator in the United States who agreed to conditionally acquired by Canopy Growth for $ 3.4 billion in a cash transaction. The condition being that the US federal government legalizes cannabis, which could happen soon, in a few years or not at all. Acreage holds licenses for nearly seven dozen retail stores in the United States and has the largest geographic presence of vertically integrated cannabis companies in 20 US states, assuming the closing of all existing acquisitions. "Data-reactid =" 95 "> Maybe it's not surprising that the eighth largest pot stock is Surface Fund (NASDAQOTH: ACRGF), a vertically integrated dispensary operator in the United States, who agreed to be conditionally acquired by Canopy Growth for $ 3.4 billion as part of a cash transaction. The condition being that the US federal government legalizes cannabis, which could happen soon, in a few years or not at all. Acreage holds licenses for nearly seven dozen retail stores in the United States and has the largest geographic presence of any vertically integrated cannabis company in 20 US states, assuming the closing of all existing acquisitions.
<h2 class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "9. Aphria: $ 1.93 billion "data-reactid =" 96 ">9. Aphria: $ 1.93 billion
Mb (0) – sm Mt (0.8em) – sm "type =" text "content =" Having been hurt by a short seller report early December and the business turnover of the management, Aphria (NYSE: APHA) returned to a market capitalization of less than $ 2 billion. But Aphria still has what could be the third-largest production portfolio in Canada, with a production capacity of 255,000 kilos per year. The Aphria management team also regularly insisted on the generation of a positive EBITDA. If the company manages to obtain a license and approve sales of its largest partner site, Aphria Diamond, and restore its profitability, Aphria has the opportunity to regain investor confidence. "Data-reactid =" 97 "> Having been hurt by a short report from the seller in early December and turnover of the management, Aphria (NYSE: APHA) returned to a market capitalization of less than $ 2 billion. But Aphria still has what could be the third-largest production portfolio in Canada, with a production capacity of 255,000 kilos per year. The Aphria management team also regularly insisted on the generation of a positive EBITDA. If the company can get a license and a sales license for its largest partner site, Aphria Diamond, and return to profitability, Aphria has the opportunity to regain investor confidence.
Two miniature caddies filled with a cannabis flower and products derived from cannabis oil.
Source of the image: Getty Images.
<h2 class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "10. Cresco Labs: $ 1.82 billion "data-reactid =" 119 ">10. Cresco Labs: $ 1.82 billion
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "In point 10, we find another Operator Cannabis dispensary clinic vertically integrated into Cresco Laboratories (NASDAQOTH: CRLBF). Although Cresco has a relatively small number of open places, he announced a change of game, Acquisition of all shares of $ 823 million the 1st of April House of origin. Origin House is a major cannabis distributor in California, which is a stylish way to say that it will help Cresco Labs integrate its branded cannabis into more than 500 California dispensaries. Although less known than other dispensary operators, Cresco should make a name for itself if the contract with Origin House is closed. "Data-reactid =" 120 "> At number 10, we find another vertically integrated cannabis dispenser operator in the United States. Cresco Laboratories (NASDAQOTH: CRLBF). Although Cresco has only a relatively small number of open sites, it announced on April 1 a fully innovative $ 823 million acquisition. House of origin. Origin House is a major cannabis distributor in California, which is a stylish way to say that it will help Cresco Labs integrate its branded cannabis into more than 500 California dispensaries. Although less known than other dispensary operators, Cresco should make a name for itself if the contract with Origin House is realized.
<h2 class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "11. Charlotte's Web Holdings: $ 1.73 Billion "data-reactid =" 121 ">11. Charlotte's Web Holdings: $ 1.73 Billion
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Charlotte Web Holdings (NASDAQOTH: CWBHF) is a manufacturer and distributor of hemp products containing CBD, the non-psychoactive cannabinoid better known for its perceived medical benefits. Having its products in nearly 3,700 stores by the end of 2018, the doors of the stores are literally and widely open for the Charlotte Web after the legalization of hemp and hemp products in December by signing the Farm Bill . It can be argued that Charlotte's Web is also one of the most profitable jar stocks at the moment. "Data-reactid =" 122 ">Charlotte Web Holdings (NASDAQOTH: CWBHF) is a manufacturer and marketer of hemp products containing CBD, the non-psychoactive cannabinoid better known for its perceived medical benefits. Having its products in nearly 3,700 stores by the end of 2018, the doors of the stores are literally and widely open for the Charlotte Web after the legalization of hemp and hemp products in December by signing the Farm Bill . Charlotte's Web is also, without a doubt, one of the most profitable jar stocks at the moment.
<h2 class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "12. HEXO: 1.51 billion dollars "data-reactid =" 123 ">12. HEXO: 1.51 billion dollars
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Although it was pulled and pulled in all directions by Wall Street analysts, hexo (NYSEMKT: HEXO) is in the enviable position of 12th largest stock of pots by market capitalization. In April 2018, HEXO landed on what still remains the longest-term cannabis supply agreement in Canada: a supply contract of 200,000 kilos with Quebec over five years, with the option for a sixth year. It also recently announced the acquisition of Newstrike Brands $ 197 million to increase its annual production peak from 108,000 to 150,000 kilograms, making HEXO one of the six largest producers in Canada. "data-reactid =" 124 "> Although it's shot by Wall Street Analysts, hexo (NYSEMKT: HEXO) is in the enviable position of 12th largest stock of pots by market capitalization. In April 2018, HEXO won what remained the most impressive long-term cannabis supply contract in Canada: a 200,000-kilogram supply contract with Quebec over five option for a sixth year. It also recently announced the acquisition of Newstrike Brands $ 197 million, which will increase its annual maximum production from 108,000 to 150,000 kg, making HEXO one of the six largest producers in Canada.
An inverted bottle of prescription lying on a doctor's notepad.
Source of the image: Getty Images.
<h2 class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "13. Trulieve Cannabis: $ 1.44 billion "data-reactid =" 146 ">13. Trulieve Cannabis: $ 1.44 billion
<p class = "web-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Continuing the theme of vertically integrated cannabis clinics in the United States United, we then Trulieve Cannabis (NASDAQOTH: TCNNF). Trulieve is laser focused on Florida, with 27 open dispensaries currently located in the Sunshine State. Again, it worked well for Trulieve, because it's one of the few stocks of pots to have delivered a profit from operations and net income. Trulieve is in the early stages of its presence in California and Massachusetts, but for now, it's mostly Florida retirees who need medical cannabis products. "Data-reactid =" 147 "> We continue on the theme of vertically integrated cannabis clinics in the United States. Trulieve Cannabis (NASDAQOTH: TCNNF). Trulieve is laser focused on Florida, with 27 open dispensaries currently located in the Sunshine State. Again, it worked well for Trulieve because it is one of the few pot stocks to have generated operating profit and net income. Trulieve is in the early stages of its presence in California and Massachusetts, but for the moment, it is mostly Florida retirees who need medical marijuana products.
<h2 class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "14. MedMen Enterprises: $ 1.32 billion"data-reactid =" 148 ">14. MedMen Enterprises: $ 1.32 billion
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Last but not least, another integrated vertically dispensary operator in MedMen companies (NASDAQOTH: MMNFF). Once one of the largest stocks of clinics, the MedMen share price fell in the wake of significant losses related to expansion. MedMen is currently in the process of acquisition of PharmaCann for $ 682 million in a stock-only transaction that, once completed, will bring its presence to a dozen states and its number of retail licenses will count at 82. As a company whose retail sales per foot square are rival Apple& nbsp; stores, the MedMen hope a quick return to glory. "data-reactid =" 149 "> Finally, another dispensary operator vertically integrated in MedMen companies (NASDAQOTH: MMNFF). Once one of the largest stocks of clinics, the MedMen share price fell in the wake of significant losses related to expansion. MedMen is in the process of acquiring PharmaCann, a private company, for $ 682 million in a fully-equity transaction that, once finalized, will strengthen its presence in a dozen states and will its number of retail licenses at 82. square foot to compete Apple stores, MedMen hopes a return to glory as soon as possible.
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = " More from The Motley Fool "data-reactid =" 150 "> More from The Motley Fool
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Sean Williams holds shares in CVS Health. The Motley Fool owns shares and recommends Apple. The Motley Fool offers the following options: $ 150 long calls on January 2020 for Apple and $ 155 calls from January 2020 on Apple. The Motley Fool recommends Constellation Brands, CVS Health, HEXO., OrganiGram Holdings and Origin House. The Motley Fool has a disclosure policy."data-reactid =" 155 ">Sean Williams owns shares in CVS Health. The Motley Fool owns shares and recommends Apple. The Motley Fool offers the following options: $ 150 long calls on January 2020 for Apple and $ 155 calls from January 2020 on Apple. The Motley Fool recommends Constellation Brands, CVS Health, HEXO., OrganiGram Holdings and Origin House. Motley Fool has a disclosure policy.
[ad_2]
Source link